BioAge Labs, Inc. and Novartis have formed a strategic alliance to combat age-related diseases.
The collaboration between BioAge and Novartis aims to enhance the understanding of the biological mechanisms underlying aging-related diseases and the positive effects of physical activity.
Novartis will provide up to $20 million in upfront payments and research funding, while BioAge stands to gain up to $530 million in potential future milestones.
BioAge's proprietary discovery platform, based on a unique dataset of longitudinal health records and functional measurements, will be further enhanced by the collaboration with Novartis.
The goal is to identify key determinants of a healthy lifespan and develop innovative drug targets for age-related conditions.
The CEO of BioAge, Kristen Fortney, has expressed confidence in the platform's ability to identify promising therapeutic pathways.
The partnership will also explore the intersection of aging biology and the biological drivers of the beneficial effects of physical exercise.
This alliance reflects the growing recognition in the medical and scientific communities that understanding the biology of aging can lead to effective treatments for various diseases.
The collaboration between BioAge and Novartis highlights the importance of interdisciplinary partnerships in addressing complex health challenges, particularly as the global population ages and the need for effective therapies for age-related diseases becomes more urgent.